Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method-Reference-Cited by-同舟云学术

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

Published:2021-02-15 Issue:5 Volume:35 Page:1161-1175
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Mrowietz U.¹^ORCID,Warren R.B.²,Leonardi C.L.³,Saure D.⁴,Petto H.⁵,Hartz S.⁶,Dossenbach M.⁵,Reich K.⁷^ORCID

Affiliation:

1. Psoriasis‐Center at the Department of Dermatology University Medical Center Schleswig‐Holstein Kiel Germany

2. Dermatology Centre Salford Royal NHS Foundation Trust Hospital Manchester NIHR Biomedical Research Centre Manchester UK

3. St. Louis University School of Medicine St. Louis MO USA

4. Lilly Deutschland GmbH Bad Homburg Germany

5. Eli Lilly Austria GmbH Vienna Austria

6. Eli Lilly and Company Ltd Windlesham UK

7. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg‐Eppendorf and Skinflammation^® Center Hamburg Germany

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.17130

Reference55 articles.

1. Definition of treatment goals for moderate to severe psoriasis: a European consensus

2. PASI90 response: the new standard in therapeutic efficacy for psoriasis

3. NastA SmithC SpulsPIet al.EuroGuiDerm Guideline for the systematic treatment of psoriasis vulgaris;2020. URLhttps://www.edf.one/dam/jcr:c80dd166‐c66f‐4548‐a7ed‐754f5e2687d0/Living_Euroguiderm_guideline_psoriasis_vulgaris.pdf(last accessed: 04 November 2020).

4. Current status and future prospects for biologic treatments of psoriasis

5. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL‐21 promoting angiogenesis contributes to the development of psoriasis;The FASEB Journal;2023-12-16

2. Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis;Journal of Clinical Medicine;2023-08-20

3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

4. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics;Italian Journal of Dermatology and Venereology;2023-01

5. A novel hyaluronic acid-based dissolving microneedle patch loaded with ginsenoside Rg3 liposome for effectively alleviate psoriasis;Materials & Design;2022-12